Aurinia Pharmaceuticals (AUPH) Stock Fundamentals, Analysis & Risk Signals

Health score, competitive moat, risk signals, and key metrics at a glance.

NasdaqGM•Healthcare•Biotechnology

ExcellentMetricSide Score: 90/100

ProfitabilityProfit25/25

GrowthGrowth25/25

Balance Sheet & Red FlagsBalance15/25

Cash & Earnings QualityCash25/25

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Price & Volume

Market Cap $1.93B

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Moat Signals

Competitive analysis based on 22 quarters of fundamental data

Pricing Power

Weak Moat

Operating margins are under pressure, averaging 26.6%. The business may lack pricing power or face rising costs.'

Competitive Advantage

Moderate Moat

ROE averages 16.8% but has fluctuated — the competitive advantage may be cyclical or emerging.

Risk Signals

Data-driven red flags and warnings across 22 quarters

Some Concerns

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Healthy

FCF covers net income by 6.1x on average — earnings are well-supported by cash generation.

Leverage Risk

Healthy

Limited debt-to-equity data available.

Revenue Decline

Healthy

Revenue is stable or growing over recent quarters — demand appears durable.

Cash Burn

Healthy

Free cash flow is consistently positive — the business self-funds without external capital reliance.

Share Dilution

Healthy

Shares decreased 7.6% — net buybacks are reducing shares outstanding and boosting per-share value.

Metrics at a Glance

as of March 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $298.30M
Q. Revenue: $77.70M
TTM EBITDA: $153.63M
TTM Op. Income: $124.49M
Q. Op. Income: $41.42M
TTM Net Income: $298.21M
Q. Net Income: $34.35M
EPS: $0.26
Shares Out.: $132.38M

$298.30M in TTM revenue grew 20.6% YoY, reaching $77.70M last quarter. TTM EBITDA of $153.63M and TTM operating income of $124.49M shows growth is flowing through. Net income of $298.21M TTM confirms the company is converting revenue into profit. Revenue is growing at a healthy pace — a signal to hold. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — a improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 91.6%
EBITDA Margin: 59.5%
Op. Margin: 53.3%
Net Margin: 44.2%

Op. margin of 53.3% is up 18.3% YoY — cost efficiency is improving. Net margin at 44.2% and gross margin of 91.6% — earnings take a bigger bite when COGS stays lean.. Across the last 8 quarters, Operating margin has risen for 3 consecutive quarters — a improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 6.5x
P/S Ratio: 6.5x
P/B Ratio: 3.4x

At 6.5x P/E, the stock trades below market averages — potentially undervalued. P/S of 6.5x and P/B of 3.4x provide additional context. Below-market P/E with growing revenue suggests a potential buying opportunity — the stock may be undervalued relative to its fundamentals. Across the last 6 quarters, P/E has fallen for 5 consecutive quarters — a improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $724.00M
Cash: $40.75M
Long-Term Debt: N/A
Book Value: $567.63M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $32.56M
TTM Free Cash Flow: $166.64M
FCF Margin: 55.9%
FCF / Net Income: 0.6

TTM FCF of $166.64M on $32.56M in operating cash flow. The FCF / Net Income ratio of 0.6x indicates partial cash conversion — earnings quality needs attention. Across the last 8 quarters, Free cash flow has risen for 7 consecutive quarters — a improving trend.